December 2025

• December 10, 2025 — Atlanta: Atlanta Small Business Expo 2025 — Georgia International Convention Center, College Park, GA. URL: https://www.eventbrite.com/e/atlanta-small-business-expo-2025-registration-1096392672999 Eventbrite
  
  

• (Also note: December 2-5: MJBizCon 2025 in Las Vegas — outside your cities, but you may want to note it.)
  
  

January 2026

• January 27, 2026 — Atlanta: Greater Atlanta Business Expo 2026 — The Auditorium, Marietta, GA. URL: https://10times.com/north-atlanta-biz-expo/visitors 10times
  
  

February 2026

• February 20-22, 2026 — Atlanta: Atlanta Black Expo 2026 — Georgia World Congress Center, Atlanta. URL: https://www.eventbrite.com/e/atlanta-black-expo-2026-tickets-1467937353139 Eventbrite
  
  

• February 9-11, 2026 — Tampa: NICA Business Expo & Fare Foods Food Show 2026 — Sheraton Tampa Brandon Hotel. URL: (site shows 2025 event; 2026 assumed) https://www.nicainc.org/event/2025-shining-bright/ NICA+1
  
  

March 2026

• March 3, 2026 — Orlando: Orlando Small Business Expo 2026 — Rosen Plaza Hotel, Orlando. URL: https://www.thesmallbusinessexpo.com/city/orlando/ Small Business Expo+1
  
  

• March 10, 2026 — Miami: Miami Small Business Expo 2026 — Miami Airport Convention Center. URL: https://www.thesmallbusinessexpo.com/city/miami/
  
  

• March 21-22, 2026 — Tampa: Tampa Franchise Trade Show & Expo 2026 — Tampa Convention Center. URL: https://www.franexpousa.com/tampa-franchise-expo-2026
  
  

April 2026

• April 13-16, 2026 — Atlanta: MODEX 2026 — Atlanta, GA (major supply-chain/manufacturing trade show). URL: https://www.modexshow.com/
  
  

• April 25-26, 2026 — Orlando: Orlando Franchise Show 2026 — Orange County Convention Center. URL: https://www.franchiseshowinfo.com/orlando-visitor
  
  

• April 29-30, 2026 — Miami: The Business Show Miami 2026 — Miami Beach Convention Center. URL: https://thebusinessshowus.com/welcome-miami The Business Show US
  
  

• April 29-30, 2026 — Miami: B2B Marketing Expo Miami 2026 — Miami Beach Convention Center. URL: https://www.b2bmarketingexpo.us/welcome-miami/ B2B Marketing Expo US 2025+1
  
  

May through November 2026

• (No additional confirmed major expos from your list in that region with full details.)
  
  

December 2026

• December 16, 2026 — Atlanta: Atlanta Small Business Expo 2026 — Georgia International Convention Center. URL: https://www.eventbrite.com/e/atlanta-small-business-expo-2026-registration-1748855396569
  
  

 HEALTH AWARENESS MONTHS

JAN — Cervical Cancer / Thyroid / Glaucoma / Migraine

• Cervical CA: 600 K global │ 13 K US yearly. CBD + curcumin reduce inflammation; folate, zinc, and AHCC boost immunity and HPV clearance.

• Thyroid: 200 M global │ 20 M US. CBD stabilizes hormones; iodine + selenium support metabolism and stress resilience.

• Glaucoma: 80 M global │ 3 M US. THC lowers eye pressure; omega-3 + laser protect vision.

• Migraine: MOVED TO JUNE

FEB — Heart Disease / Cancer / PTSD / Fibromyalgia

• Heart: 550 M global │ 697 K US deaths yearly. CBD + omega-3 lower BP; CoQ10 + turmeric improve vascular tone.

• Cancer: 20 M global │ 1.9 M US. THC/CBD ease chemo pain; IV vit C + hyperthermia improve recovery.

• PTSD: 350 M global │ 13 M US. CBN + ketamine calm fear circuitry; EMDR builds resilience.

• Fibromyalgia: 100 M global. CBD, 5-HTP, and magnesium improve sleep and reduce central sensitization.

MAR — Brain Injury / Colorectal CA / MS / Anxiety

• TBI: 69 M global │ 1.5 M US. CBD + omega-3 repair neurons; ketamine + rehab enhance neuroplasticity.

• CRC: 1.9 M global │ 150 K US. Curcumin + fiber reduce tumor growth; cannabis eases abdominal pain.

• MS: 2.8 M global. CBD/THC mix reduces spasticity; vitamin D + B12 enhance myelin repair.

• Anxiety: 301 M global │ 42 M US. CBD + mindfulness reduce cortisol; adaptogens like ashwagandha stabilize mood.

APR — Autism / Alcohol Abuse / Epilepsy / Financial Stress

• Autism: 75 M global │ 1 in 36 US kids. CBD eases anxiety; B6 + magnesium aid cognition.

• Alcohol use: 283 M global │ 140 K US deaths. IV B-complex detox + cannabis reduce cravings.

• Epilepsy: MOVED TO NOVEMBER

• Financial anxiety: 200 M global. Budget therapy + journaling reduce pain flare frequency and insomnia.

MAY — Mental Health / Arthritis / Back Pain / Burnout

• Depression: 300 M global │ 21 M US. Ketamine + omega-3 elevate mood; magnesium + CBD aid serotonin.

• Arthritis: 350 M global │ 53 M US. PRP + CBG relieve joints; curcumin + collagen rebuild cartilage.

• Back Pain: 619 M global │ 65 M US. CBD + epidural steroids relieve inflammation; posture therapy prevents relapse.

• Burnout: 400 M global. Adaptogens + mindfulness + B12 restore energy.

JUN — Men's Health / MIGRAINE / ED / Sleep

• Prostate: 1.4 M global │ 288 K US. Saw palmetto + zinc improve flow; CBD + low-dose THC reduce pain.

• Migraine: 1 B global │ 39 M US. Botox + CBD block pain; magnesium + riboflavin reduce triggers.

• ED: 320 M global. PRP + shockwave restore circulation; L-arginine boosts nitric oxide.

• Insomnia: 1 B global │ 70 M US. CBN + melatonin restore REM; magnesium glycinate calms nerves.

JUL — Minority Mental Health / Skin Cancer / PTSD / Burnout

• PTSD: 350 M global │ 13 M US. Ketamine infusions reset trauma pathways; CBN + CBD aid rest.

• Skin Cancer: 1 M global │ 5.5 M US. Topical CBD + vitamin D reduce UV-induced DNA damage.

• Burnout: 400 M global. Omega-3, mindfulness, and social support prevent physician fatigue.

AUG — Immunization / Psoriasis / Autoimmune / Chronic Fatigue

• Psoriasis: 125 M global │ 7.5 M US. CBD + turmeric calm inflammation; UVB phototherapy enhances skin renewal.

• Lupus: 5 M global │ 200 K US. Omega-3 + CBD lower flares; vitamin D + CoQ10 aid immunity.

• Chronic Fatigue: 150 M global. NAD+ IVs + adaptogens restore mitochondrial energy.

SEP — Chronic Pain / Prostate CA / Neuropathy / Addiction

• Chronic Pain: 1.5 B global │ 50 M US. THC/CBD ↓ opioid need > 60%; nerve blocks + acupuncture improve function.

• Prostate CA: 1.4 M global │ 288 K US. CBD reduces bone pain; lycopene + vit D support prevention.

• Neuropathy: 240 M global. Alpha-lipoic acid + CBG + IV B12 repair nerves.

• Addiction: 200 M global. Cannabis + ketamine-assisted therapy improve long-term recovery.

OCT — Breast CA / Depression / Osteoporosis / Financial Toxicity

• Breast CA: 2.3 M global │ 300 K US. CBD + CBG relieve chemo pain; omega-3 aid tissue repair.

• Depression: 300 M global │ 21 M US. Ketamine + 5-HTP lift mood; mindfulness builds resilience.

• Osteoporosis: 500 M global │ 10 M US. PRP + vitamin K2 + weight training increase bone density.

• Financial toxicity: 80% cancer patients affected — budgeting + advocacy reduce distress.

NOV — Lung CA / Diabetes / COPD / EPILEPSY / Pain Crisis

• Lung CA: 2.2 M global │ 234 K US. CBD + vit C IV reduce fatigue; THC aids appetite and mood.

• Diabetes: 540 M global │ 38 M US. CBG + berberine enhance glucose control; magnesium supports insulin.

• COPD: 390 M global │ 16 M US. Nebulized CBD + breathing rehab improve oxygenation.

• Epilepsy: 65 M global │ 3 M US. CBD (Epidiolex) FDA-approved; ketogenic diet aids seizure control.

• Pain crisis: 1.5 B global. Multimodal pain + cannabis reduce ER visits.

DEC — HIV/AIDS / Road Injury / Insomnia / Holiday Stress

• HIV: 39 M global │ 1.2 M US. CBD ↑ appetite; B-complex + omega-3 boost immunity.

• Traffic injury: 1.3 M global deaths │ 46 K US. Post-injury PRP + CBD ↓ opioid reliance.

• Insomnia: 1 B global │ 70 M US. CBN + magnesium improve rest.

• Holiday stress: Mindfulness + CBD tea ↓ cortisol; gratitude resets the brain.

Foundation / ECS & Well-Being

Pain Awareness Month! 🎗️
Let’s spotlight research that enhances not just symptom relief but whole-person wellness.

📖 “Changes in health-related quality of life over the first three months of medical marijuana use” (Journal of Cannabis Research, 2024 – Lent et al.)

• In a prospective observational study (n = 438; average age 46.4 years, 66% female), researchers assessed 8 SF-36 domains before and after 3 months of medical cannabis 

• Gains across all domains: physical functioning, pain, emotional well-being, social role, vitality, and general health—all improved significantly (P < .001)  

• Age effect: Younger participants experienced greater gains in pain and physical function.
  These improvements suggest that cannabis can enhance quality of life broadly—especially in emotional and social domains—underscoring its potential beyond pain control.
  
  

🔗 Read the full study: https://pubmed.ncbi.nlm.nih.gov/39256884/

How might these QoL gains influence clinical conversations and patient goals? 👇

@Abigail

@Alexandra

@Angela

@Claucous

@Roz

@Ignacio

@Jacody

@Jacquie

@Janice

@Jodeci

@Joseph

@Joseph

@Jordan

@Mary

@Rasean

@Renee

@Saige

@Scheril

@Shoshanna

@Travis

@Vincent

@Zach 

Sept 3 — ECS & Well-Being

Pain Awareness Month! 🎗️
Let’s explore the science underpinning cannabis’ effect on pain.

📖 “The endocannabinoid system as a therapeutic target in neuropathic pain: a review” (Expert Opinion on Therapeutic Targets, 2024 – Quintero et al.)

• Comprehensive review of preclinical and clinical data illustrating how CB1 and CB2 receptors, along with endocannabinoid metabolism enzymes, regulate neuropathic pain pathways.

• Summarizes future direction: exploring targeted agonists/modulators, optimizing dosing via modulation of endocannabinoid tone, and identifying biomarkers.

By understanding ECS mechanisms, we can refine therapeutic strategies, improve dosing precision, and design better trials—linking theory to practice.

🔗 Read the abstract: https://pubmed.ncbi.nlm.nih.gov/39317147/

Could broader ECS education among clinicians improve comfort with cannabis? 👇

Sept 4 — Fundamentals & Calculations

Pain Awareness Month! 🎗️
Let’s anchor care in iterative, transparent evidence.

📖 “Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain” (AHRQ, 2024)

• A dynamic, continuously updated review of RCTs evaluating non-inhaled cannabis therapies (oils, capsules, sprays) for chronic pain and sleep improvements

• Small but consistent benefits, particularly with oral/oromucosal forms.

• Most adverse events—dizziness, sedation, nausea—were mild and transient.
  This model ensures practice stays aligned with the latest findings as new trials emerge.
  
  

🔗 Read the full report: https://www.ncbi.nlm.nih.gov/books/NBK613700/

Would you prefer living reviews to static guidelines in such a fast-evolving field? 👇

Sept 5 — Fundamentals & Calculations

Pain Awareness Month! 🎗️
How does cannabis measure up to opioids in real comparative terms?

📖 “Cannabis for medical use versus opioids for chronic non-cancer pain: a systematic review and network meta-analysis” (BMJ Open, 2024 – Jeddi et al.)

• Pooled data from 90 RCTs (n = 22,028) comparing cannabis, opioids, and placebo for chronic pain. Cannabis delivered comparable outcomes in terms of pain, sleep, and function.

• Safer profile: Cannabis was associated with significantly fewer adverse-effect-related dropouts (OR 0.55) and lacked risks like respiratory depression or overdose.
  
  

These findings suggest cannabis may offer the same clinical benefit with markedly better tolerability, reshaping frontline treatment decisions.

🔗 Read the study: https://pubmed.ncbi.nlm.nih.gov/38171632/

Should guidelines prioritize safety-first options when efficacy is equivalent? 👇

Sept 6 — Fundamentals & Calculations

Pain Awareness Month! 🎗️
Ratios matter—as metabolism of THC shifts with CBD co-administration.

📖 “Assessment of Orally Administered Δ9-THC When Coadministered With Cannabidiol on Δ9-THC Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial” (JAMA Network Open, 2023 – Zamarripa et al.)

• In an RCT, healthy adults received 20 mg THC alone or with 640 mg CBD. Co-administration slowed THC metabolism, increasing exposure (Cmax, AUC).

• Clinically relevant: Patients reported greater sedation, anxiety, and cognitive changes with combined use.
  
  

This illustrates how THC:CBD ratios matter significantly for both efficacy and side effect risk—critical in prescribing decisions.

🔗 Read the study: https://pubmed.ncbi.nlm.nih.gov/36780161/

How do you choose the right ratio for a new patient? 👇

Sept 7 — Safety First: Side Effects & Monitoring

Pain Awareness Month! 🎗️
Let’s ground care with long-term safety data—not just short-term trials.

📖 “Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: a systematic review of non-randomised studies” (BMJ Open, 2022 – Zeraatkar et al.)

• Synthesized observational data on long-term cannabis use in chronic pain. Serious adverse events were rare, <5%; common AEs were mild—e.g., dizziness, sedation.

• Importantly, no sustained harm signals, supporting long-term supervised use.
  
  

This offers reassurance that, with structured monitoring, cannabis can be safe over time—a confidence builder for caregivers and patients alike.

🔗 Read the study: https://pubmed.ncbi.nlm.nih.gov/35926992/

What safety checkpoints do you use for long-term cannabis patients? 👇

Sept 8 — Safety First: Risks, Side Effects & Monitoring

Pain Awareness Month! 🎗️
Let’s ground our care in long-term safety plus patient-reported outcomes.

📖 “Assessment of Medical Cannabis and Health-Related Quality of Life” (JAMA Network Open, 2023 – Arkell et al.)

• Design & size: Large case series (n = 3,148; mean age ~56). Patients initiated medical cannabis for diverse conditions and were followed prospectively.

• Outcomes: Significant improvements across all 8 SF-36 domains after initiation (physical function, pain, vitality, social, emotional, general health), with benefits mostly sustained over time.

• Safety: Adverse events were common but rarely serious—reinforcing the need to start low, go slow, and monitor.
  Real-world data show meaningful quality-of-life gains with an acceptable safety profile when therapy is supervised.
  
  

🔗 Read the full study: https://pmc.ncbi.nlm.nih.gov/articles/PMC10170337/ PMC
What’s your go-to monitoring plan (AEs, PROMs, follow-up cadence)? 👇

Sept 9 — Safety First: Drug–Drug Interactions & Monitoring

Pain Awareness Month! 🎗️
Polypharmacy is real—DDIs can make or break outcomes.

📖 “Systematic Review of Drug–Drug Interactions of Δ9-Tetrahydrocannabinol and Cannabidiol” (Frontiers in Pharmacology, 2024 – Nachnani et al.)

• Scope: Screened 4,600 reports; analyzed 151 full-text items with real-world, documented cannabinoid interactions.

• Key risks: CYP450-mediated interactions (e.g., warfarin/INR changes, clobazam/sedation, tacrolimus/levels). Additive CNS depression with opioids/benzodiazepines.

• Clinical move: Baseline med reconciliation, select labs (e.g., INR, LFTs), slow titration, and pharmacist collaboration—especially in older adults.
  Thoughtful DDI screening preserves benefits while preventing avoidable harm.
  
  

🔗 Read the study: https://pmc.ncbi.nlm.nih.gov/articles/PMC11167383/ PMC
What’s in your DDI checklist before starting cannabis? 👇

Sept 10 — Lower Back Pain & Osteoarthritis

Pain Awareness Month! 🎗️
Edibles can be practical—dose and ratio matter.

📖 “Edible Cannabis for Chronic Low Back Pain: Associations with Pain, Mood, and Intoxication” (Frontiers in Pharmacology, 2024 – Melendez-Torres et al.)

• Design: Naturalistic study (n = 249) tracking 2-week ad-lib use plus an acute, observed session.

• Analgesia: During acute use, higher THC dose ↔ greater short-term pain relief (p < .05). Across 2 weeks, overall pain decreased; CBD-dominant use trended toward lower pain (p = .07).

• Tolerability: THC dose correlated with intoxication and tension; CBD linked with tension relief.
  Bottom line: Edibles can help cLBP; calibrate THC:CBD for relief vs side effects and counsel on onset/duration.
  
  

🔗 Read the full study: https://pmc.ncbi.nlm.nih.gov/articles/PMC11458467/ PMC
Your favorite edible titration schedule for cLBP? 👇

Sept 11 — Lower Back Pain & Osteoarthritis

Pain Awareness Month! 🎗️
Real-world registry data show multi-domain gains in OA.

📖 “Assessment of Clinical Outcomes in Patients With Osteoarthritis: Analysis From the UK Medical Cannabis Registry” (J Pain & Palliative Care Pharmacotherapy, 2024 – Francis et al.)

• Design & size: Prospective case series (n = 77), follow-up at 1/3/6/12 months.

• Pain & function: BPI pain severity (p = .004), interference (p = .005) and MPQ-2 (p = .017) improved at all follow-ups.

• QoL & sleep: EQ-5D-5L (p = .026) and sleep (p < .001) improved up to 6 months; GAD-7 improved to 3 months (p = .038).

• Safety: Most AEs mild–moderate; severe AEs were less common—supports structured oversight.
  OA patients reported broad, durable gains when CBMPs were prescribed and monitored.
  
  

🔗 Read the abstract: https://pubmed.ncbi.nlm.nih.gov/38669060 PubMed
Which PROMs will you track first in OA (BPI, EQ-5D-5L, sleep)? 👇

Sept 12 — Lower Back Pain & Osteoarthritis

Pain Awareness Month! 🎗️
Local relief with minimal systemic exposure is attractive in OA.

📖 “An Open-Label Feasibility Trial of Transdermal Cannabidiol for Hand Osteoarthritis” (Scientific Reports, 2024 – Bawa et al.)

• Protocol: 4% CBD gel, 3×/day, 4 weeks, applied to the most painful hand.

• Results: Current, average, and max pain fell by ~1.9/10 on NPRS (all p < .0001). Grip strength increased (p < .0001).

• QoL: Sleep, fatigue, stiffness, anxiety improved (p < .005). Urine testing suggested low systemic CBD exposure.
  Feasibility data support topical CBD for hand OA—now primed for placebo-controlled trials.
  
  

🔗 Read the article: https://www.nature.com/articles/s41598-024-62428-x Nature
Would you trial topical CBD before oral options in hand OA? 👇

Sept 13 — Lower Back Pain & Osteoarthritis

Pain Awareness Month! 🎗️
Route of administration changes onset, durability—and outcomes.

📖 “Comparing Sublingual and Inhaled Cannabis Therapies for Low Back Pain: An Observational Open-Label Study” (Rambam Maimonides Medical Journal, 2022 – Robinson et al.)

• Design: Sequential treatment with CBD-rich sublingual extracts (10 mo) then THC-rich inhaled flower (≥12 mo), with washouts.

• Efficacy: VAS pain, Oswestry Disability Index, and SF-12 Physical improved; inhaled therapy outperformed sublingual for pain relief at 18–24 months.

• Takeaway: Inhalation offers rapid, meaningful relief for persistent LBP when counseled on dosing and safety.
  Mechanism + route pairing lets you match breakthrough vs baseline control.
  
  

🔗 Read the full paper: https://pmc.ncbi.nlm.nih.gov/articles/PMC9622393/ PMC
How do you choose between inhaled, oral, and topical for LBP? 👇

Sept 14 — Fibromyalgia, Headaches & Neuropathy

Pain Awareness Month! 🎗️
Finally—an RCT for acute migraine with robust, sustained effects.

📖 “Vaporized Cannabis Versus Placebo for Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial” (Headache, 2024 – Schuster et al.)

• Design & size: 92 adults, 247 attacks; participants treated up to 4 attacks with THC+CBD, THC-dominant, CBD-dominant, or placebo.

• Efficacy at 2 h (THC+CBD): Pain relief 67.2% vs 46.6%, pain freedom 34.5% vs 15.5%, MBS freedom 60.3% vs 34.5%—with sustained benefits at 24–48 h.

• Safety: No serious AEs; THC+CBD outperformed THC-only on tolerability.
  Clinically, a balanced THC:CBD profile delivered rapid and durable relief in a rigorously controlled design.
  
  

🔗 Read the full study: https://pmc.ncbi.nlm.nih.gov/articles/PMC10889030/ PMC
If you built a migraine protocol, how would you time dosing vs onset? 👇

Sept 15 — Fibromyalgia, Headaches & Neuropathy

Pain Awareness Month! 🎗️
Let’s highlight evidence on whole-patient outcomes in fibromyalgia.

📖 “Effectiveness and safety of cannabis-based products for medical use in patients with fibromyalgia syndrome: a systematic review” (Exploration of Research and Clinical Social Pharmacy, 2024 – Lopera et al.)

• Scope & methods: Systematic review of 19 publications on cannabis-based medicines (e.g., nabilone, oils, vaporized forms) for fibromyalgia.

• Signals of benefit: Across studies, patients commonly reported reduced pain, improved sleep, and better quality of life; no serious AEs were reported.

• Evidence caveats: Heterogeneous dosing/routes and study quality → authors call for larger, well-controlled RCTs.
  These findings suggest medical cannabis can address multi-symptom burden in fibromyalgia when individualized and monitored—while underscoring the need for stronger RCTs.
  
  

🔗 Read the full study: https://pubmed.ncbi.nlm.nih.gov/39498228/ (free full text via PMC inside). PubMed
What dosing/form routes have you seen work best for fibro symptoms? 👇

Sept 16 — Fibromyalgia, Headaches & Neuropathy

Pain Awareness Month! 🎗️
Neuropathic pain demands targeted options—transdermal is one to watch.

📖 “Efficacy and Safety of Transdermal Medical Cannabis (THC:CBD:CBN) to Treat Painful Diabetic Peripheral Neuropathy of Lower Extremities: A Double-Blind, Randomized, Placebo-Controlled Trial” (Medical Cannabis and Cannabinoids, 2024 – Seevathee et al.)

• Design & size: 12-week RCT; ~100 participants randomized to active transdermal THC:CBD:CBN vs placebo.

• Primary outcome: NPSI total improved markedly (~25.6 → 5.6 active vs 25.2 → 22.9 placebo).

• Safety: Mild AEs ~10%, favorable tolerability across visits.
  This study shows robust neuropathic pain reduction with a local, non-oral formulation—useful when systemic exposure or polypharmacy is a concern.
  
  

🔗 Read the full study: https://pmc.ncbi.nlm.nih.gov/articles/PMC11666268/ (PubMed: 39720705). PMCPubMed
Would you trial transdermal for focal neuropathic pain before oral agents? 👇

Sept 17 — Mental Health: Anxiety, PTSD & Depression

Pain Awareness Month! 🎗️
Sleep and well-being often move together—here’s what a controlled trial found.

📖 “Cannabidiol for moderate–severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing” (J Clin Sleep Med, 2024 – Narayan et al.)

• Design: Parallel RCT, n = 30 (15 CBD vs 15 placebo), 2-week dosing after a single-blind run-in; outcomes via actigraphy, diaries, and validated scales.

• Results: Most sleep outcomes did not differ vs placebo; however, CBD produced higher well-being throughout and better objective sleep efficiency at 2 weeks.

• Implication: Signals point to psychological/SE benefits at 150 mg nightly; authors recommend larger, longer trials and dose-finding work.
  Clinically, CBD may support well-being and selected sleep metrics in insomnia—best framed as adjunctive with careful expectation setting.
  
  

🔗 Read the full study: https://pmc.ncbi.nlm.nih.gov/articles/PMC11063694/ (PubMed: 38174873). PMC
How would you combine sleep hygiene + CBD in a stepwise plan? 👇

Sept 18 — Mental Health: Anxiety, PTSD & Depression

Pain Awareness Month! 🎗️
Prospective data on PTSD and sleep can guide real-world care.

📖 “Improved Post-Traumatic Stress Disorder Symptoms and Related Sleep Disturbances after Initiation of Medical Marijuana Use: Evidence from a Prospective Single-Arm Pilot Study” (Medical Cannabis and Cannabinoids, 2023 – Vaddiparti et al.)

• Design: Prospective pilot, n = 15 adults with confirmed PTSD; assessments at ~30 and ~70 days after starting medical cannabis.

• Findings: PTSD symptoms (PCL-5) decreased, nightmares reduced, and sleep quality (PSQI) improved; tolerability acceptable.

• Caveat: Single-arm design (no placebo) → hypothesis-generating, not definitive.
  These patient-reported improvements—especially for nightmares and sleep—support structured trials and close monitoring when adding cannabis to PTSD care.
  
  

🔗 Read the study: https://pubmed.ncbi.nlm.nih.gov/37965569/ (publisher open access). PubMed
What PTSD measures (PCL-5, PSQI) would you track in clinic? 👇

Sept 19 — Mental Health: Anxiety, PTSD & Depression

Pain Awareness Month! 🎗️
A synthesis of CBD’s anxiolytic potential across diagnoses.

📖 “Therapeutic potential of cannabidiol (CBD) in anxiety: a systematic review and meta-analysis” (Psychiatry Research, 2024 – Han et al.)

• Scope: Meta-analysis of controlled studies in GAD, SAD, PTSD and related anxiety states.

• Signals: Pooled effects favor CBD for anxiety reduction, though trial sizes are modest and regimens vary (dose/formulation).

• Safety: Generally well tolerated; sedation and DDI considerations remain.
  Bottom line: Emerging evidence supports diagnosis-specific, cautious CBD use for anxiety—best within a monitored, stepwise plan.
  
  

🔗 Read the study: https://pubmed.ncbi.nlm.nih.gov/38924898/ (publisher link inside). PubMed
Your CBD guardrails (dose range, duration, follow-up) for anxiety? 👇

Sept 20 — Cancer Patients: Symptom Relief & Risks

Pain Awareness Month! 🎗️
Adjunctive antiemetic support matters when standard prophylaxis isn’t enough.

📖 “Oral cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: final results of a randomized, placebo-controlled, phase II/III trial” (Journal of Clinical Oncology, 2024 – Grimison et al.)

• Design & size: Multicenter RCT; 147 evaluable patients receiving guideline prophylaxis ± oral THC:CBD.

• Primary endpoint: Complete response (0–120 h) was 24% with THC:CBD vs 8% with placebo.

• Safety: More sedation/dizziness in the THC:CBD arm; no new safety signals.
  For patients with difficult-to-control CINV, adding 1:1 THC:CBD can improve outcomes—balanced with counseling on sedation.
  
  

🔗 Read the study: https://pubmed.ncbi.nlm.nih.gov/39151115/ (ASCO full text via DOI inside). PubMedASCO Publications
How do you layer cannabinoids alongside NK1/5-HT3/DEX regimens? 👇

Sept 21 — Cancer Patients: Symptom Relief & Risks

Pain Awareness Month! 🎗️
Crossover evidence in gynecologic oncology adds practical nuance.

📖 “Oral Tetrahydrocannabinol (THC):Cannabidiol (CBD) Cannabis Extract Adjuvant for Reducing Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial” (International Journal of Women’s Health, 2023 – Sukpiriyagul et al.)

• Design: Crossover RCT, n = 54 analyzed; each patient received 1:1 THC:CBD and placebo across two chemo cycles (with standard antiemetics).

• Outcome: Lower nausea scores with THC:CBD vs placebo (~2.11 vs 2.99, P < 0.05); dizziness/sedation were common but manageable.

• Clinical fit: Useful adjunct in moderate–high emetogenic regimens, with counseling on CNS effects and timing.
  These results reinforce the antiemetic role of balanced THC:CBD in real-world oncology cycles.
  
  

🔗 Read the full study: https://pmc.ncbi.nlm.nih.gov/articles/PMC10440684/ (PubMed: 37608911).
What’s your go-to plan for breakthrough CINV despite guideline therapy? 👇